Regions
Abbott, Mylan silent on why changing tax-inversion terms
Drugmakers Abbott Laboratories (ABT.N) and Mylan Inc (MYL.O) on Wednesday declined to explain in detail why they changed the terms of a $5.3 billion deal in which Mylan will buy part of Abbott's overseas generics business and reincorporate for tax purposes in the Netherlands.
Private equity eyes $13 billion Bayer plastics business
Private equity firms are circling Bayer's (BAYGn.DE) 10 billion-euro ($12.7 billion) plastics business, hoping to divert the German drugmaker from its plan to list the division, two people familiar with the matter said on Wednesday.
Boeing books first sales to Iran since 1979
Boeing said on Wednesday it had sold aircraft-related goods to Iran Air in the third quarter, marking the first acknowledged dealings between U.S. aerospace companies and Iran since the 1979 U.S. hostage crisis.
Advent, Avista near deal for UCB's Kremers Urban
A consortium of buyout firms Advent International Corp and Avista Capital Partners is in advanced talks to acquire UCB SA's (UCB.BR) U.S. generic drugs unit Kremers Urban Pharmaceuticals Inc, according to people familiar with the matter.